TOBAF - TAAT Announces Filing of Audited and Q1 Financial Statements
(TheNewswire)
LAS VEGAS and VANCOUVER – TheNewswire - June 28, 2024 – TAAT®GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTC: TOBAF) (FRANKFURT: 2TP)(the “Company” or “TAAT®”) is pleasedto confirm that further to its news release dated May 15, 2024, theCompany has filed on SEDAR+ its audited financial statements,accompanying management discussion and analysis and related CEO andCFO certifications for the period ended October 31, 2023 (the"Annual Filings") and its interim Q1 financail statements,accompanying management discussion and analysis and related CEO andCFO certifications for the period ended January 31, 2024 (the"Quarterly Filings"). The Annual Filings and QuarterlyFilings can be obtained on the Company's SEDAR+ profile atwww.sedarplus.ca.
The cease trade order issued by the British ColumbiaSecurities Commission On May 14, 2024 has now been revoked and theCompany has been reinstated for trading on the Canadian SecuritiesExchange.
On behalf of the Board of Directors of theCompany,
TAAT® GLOBAL ALTERNATIVES INC.
“Michael Saxon”
Michael Saxon, CEO and Director
For further information, please contact:
TAAT® Investor Relations
1-833-TAAT-USA (1-833-822-8872)
investor@taatglobal.com
THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOTREVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY ORADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATIONSERVICES PROVIDER.
About TAAT® Global Alternatives Inc.
TAAT® is a vertically integrated consumer product anddistribution company, generating more than CAD $90 million in overallgross revenue annually. TAAT® is strategically expanding its productcategories including tobacco and reduced-risk alternatives, hemp,kratom, and other emerging CPG segments. TAAT® has facilities toinclude a processing plant in Nevada as well as a distribution centrein Canton, Ohio, leveraging existing retail shelf space and pipelinesinto national wholesale channels.
For more information, please visit http://taatglobal.com .
Forward-Looking Statements
Certain information contained herein may constitute"forward-looking information" or "forward-lookingstatements" under Canadian securities legislation. Generally,forward-looking information can be identified by words such as"pro forma", "plans", "expects","may", "should", "could","will", "budget", "scheduled","estimates", "forecasts", "intends","anticipates", "believes", or variations includingnegative variations thereof of such words and phrases that refer tocertain actions, events or results that may, occur or be taken orachieved. Such forward-looking statements, including but not limitedto statements relating to the expected development and operations ofthe Company, involve risks, uncertainties and other factors which maycause the actual results to be materially different from thoseexpressed or implied by such forward-looking statements orforward-looking information. There can be no assurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements and forward-lookinginformation. The Corporation will not update any forward-lookingstatements or forward-looking information included herein, except asrequired by applicable securities laws.
The statements in this news release have not beenevaluated by Health Canada or the U.S. Food and Drug Administration.As each individual is different, the benefits, if any, of taking theCompany’s products will vary from person to person. No claims orguarantees can be made as to the effects of the Company’s productson an individual’s health and well-being. The Company’s productsare not intended to diagnose, treat, cure, or prevent anydisease.
This news release may contain trademarked names ofthird-party entities (or their respective offerings with trademarkednames) typically in reference to (i) relationships had by the Companywith such third-party entities as referred to in this release and/or(ii) client/vendor/service provider parties whose relationship withthe Company is/are referred to in this release. All rights to suchtrademarks are reserved by their respective owners orlicensees.
Statement Regarding Third-Party Investor RelationsFirms
Disclosures relating to investor relations firmsretained by TAAT® Global Alternatives Inc. can be found under theCompany's profile on http://sedarplus.ca .
Copyright (c) 2024 TheNewswire - All rights reserved.